Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241563 · ClinicalTrials.gov registry record · Phase 4
Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat
A Phase 4 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT03241563 is a Phase 4 study that has completed, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 20 participants.
The verdict
NCT03241563, a Phase 4 study, has completed, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The subjects and evaluating investigator will be blinded to the treatment, thus maintaining double-blind status. By nature of the varying volumes of injection, the treating investigator will be unblinded to the treatment. A series of 3 injection sessions will be performed spaced 4 weeks apart. Canfield Vectra 3D imaging will be performed at baseline and at each follow up visit. Follow up visits will be performed 3 and 5 days after each injection session to assess for side effect and tolerability profile. After the final injection session, additional follow up visits will be performed at days 90 and 180 to assess for efficacy. Subject weight will be recorded at baseline and at end of study.
Interventions
- DRUG Triamcinolone
- DRUG Sodium Deoxycholate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03241563
The ClinicalTrials.gov registry entry for NCT03241563 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone is the first listed.
NCT03241563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03241563 about?
NCT03241563 is a clinical study titled "Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat". The subjects and evaluating investigator will be blinded to the treatment, thus maintaining double-blind status. By nature of the varying volumes of injection, the treating investigator will be unblinded to the treatment. A series of 3 injection sessions will be performed spaced 4 weeks apart. Canf...
What is the current status of trial NCT03241563?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2016-04. Estimated completion is 2017-02.
What interventions are being tested in trial NCT03241563?
The interventions under investigation include: Triamcinolone (DRUG), Sodium Deoxycholate (DRUG).
Who is sponsoring clinical trial NCT03241563?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.